


# COMPARE CRUSH



AMERICAN COLLEGE of CARDIOLOGY

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention


Investigator-initiated, multicenter, randomized controlled trial



**Objective:** To compare the use of pre-hospital crushed oral P2Y<sub>12</sub> inhibitor prasugrel with integral tablets in patients presenting with STEMI and being considered for primary PCI (pPCI).


**727 patients**

**Inclusion criteria:** Patients with suspected STEMI and symptom onset within 6 hours who were initially managed by mobile emergency care unit with plan for primary PCI were included in the study.



**Crushed prasugrel (N=369)**

**VS**



**Integral prasugrel (N=358)**

## PRIMARY OUTCOME

**31**

**TIMI 3 flow before pPCI %**  
OR 0.92; 95% CI 0.65-1.30; P=0.64

**32.7**

**59.9**

**Complete ST-segment resolution 1 hr after pPCI %**  
OR 1.11; 95% CI 0.78-1.58; P=0.55

**57.3**

## SECONDARY OUTCOME

**43.3**

**High platelet reactivity at start of PCI (P2Y<sub>12</sub> inhibitor reactivity units >208) %**  
P<0.01

**62.6**

**Conclusion:** Pre-hospital administration of crushed prasugrel tablets does not improve TIMI 3 flow in the infarct related artery pre-pPCI or complete ST-segment resolution 1h post-pPCI in patients presenting with STEMI planned for pPCI.